Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax: The Bull Has Pummeled The Bear 19 Times In A Row And Is Ready To Strike Again

San Diego, California--(Newsfile Corp. - January 6, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc., No. 21-cv-02910. Filed on November 12, 2021 in the District of Maryland, the Novavax class action lawsuit charges...

UPCOMING DEADLINE: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NVAX

NEW ORLEANS, Jan. 5, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period").

NOVAVAX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novavax, Inc. - NVAX

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NVAX FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Novavax, Inc. Investors With Losses to Secure Counsel Before Important January 11 Deadline in Securities Class Action - NVAX

Boston, Massachusetts--(Newsfile Corp. - January 5, 2022) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

NVAX ALERT: Thornton Law Firm Reminds Novavax Investors of Securities Class Action

Los Angeles, California--(Newsfile Corp. - January 5, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Tuesday Deadline Reminder: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

It would represent a gain of more than 100%.

Will Novavax Stock Hit $300 in 2022?

GAITHERSBURG, Md., Jan. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the virtual 40th Annual J.P.

Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Los Angeles, California--(Newsfile Corp. - January 4, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

7-Day Deadline Reminder: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Ocugen, Inc.

Pfizer

Investors seem to be seeing a light at the end of the tunnel with the COVID-19 pandemic despite the present darkness.

Why Pfizer, Novavax, and Ocugen Stocks Are Sinking Today

Intercept Pharma

Madrigal Pharmaceuticals

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

3 Biotech Stocks With Major Catalysts in January

Moderna

Both of these coronavirus vaccine innovators have plenty of upside in 2022.

Better Buy: Novavax vs. Moderna

The stock keeps going down despite having good news.

Is It Time to Throw in the Towel on Novavax?

Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.

Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine

Still a vaccine play with high potential, consider NVAX stock a buy at today's prices. The post Don't Read Too Much into Novavax's Recent Pullback appeared first on InvestorPlace.

Don't Read Too Much into Novavax's Recent Pullback

Boston, Massachusetts--(Newsfile Corp. - January 3, 2022) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

Thornton Law Firm Reminds Novavax, Inc. (NVAX) Investors of Securities Class Action

Novavax remains poised to sell its coronavirus vaccine to many countries around the world, giving NVAX stock a strong revenue stream in 2022. The post Some Investors Should Buy Novavax Stock on the Dip appeared first on InvestorPlace.

Some Investors Should Buy Novavax Stock on the Dip

Alliance Resource Partners

Axon Enterprise

BARK

EverBank Financial

GrowGeneration Corp

Kinross Gold

Kulicke & Soffa Industries

Lumber Liquidators

Lovesac Company

Opendoor

Ping Identity Holding Corp

Pinterest

Proto Labs

Pubmatic

Root

StoneCo

Teva Pharmaceutical

Triple-digit returns could be just a click of the buy button away.

22 Stocks That Could Double Your Money in 2022

Radnor, Pennsylvania--(Newsfile Corp. - January 2, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. Shareholders of Securities Class Action Lawsuit and Urges Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Jan. 1, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. That A Securities Fraud Class Action Lawsuit Has Been Filed on Their Behalf

Vertex Pharmaceuticals

These two biotechs look like great buys heading into 2022.

2 Best Stocks to Invest $5,000 in Right Now

Here's what's driving the price performance in Novavax and NVAX stock right now, as the stock sinks 4% today on a lower-volume day. The post NVAX Stock Alert: What Is Going on With Novavax Today?

NVAX Stock Alert: What Is Going on With Novavax Today?

GAITHERSBURG, Md., Dec. 31, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has completed submission of the final data package, including the complete chemistry, manufacturing and controls module, to fulfill the prerequisites for emergency use authorization (EUA) application request to the U.S. Food and Drug Administration (FDA) for NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine

Amazon

Salesforce

Trulieve Cannabis Corp.

Even though it's Dec. 31, investors have extra time to make smart moves with their money.

It's Not Too Late to Add These 5 No-Brainer Stocks to Your IRA in 2021

CEDARHURST, N.Y., Dec. 30, 2021 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period").

News for Novavax Stock (NVAX)